Últimos ensayos

EudraCT Number: 2008-001560-37

Sponsor Protocol Number: GEM-658-EBE-0024-I

Start Date:

Sponsor Name: Medizinische Fakultät der TU-München, vertreten durch den Dekan

Full Title: Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom

Medical condition: - advanced cholangiocarcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10008594	Cholangiocarcinoma non-resectable	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2014-005391-29

Sponsor Protocol Number: 2021/2014

Start Date:

Sponsor Name: Medical University of Vienna

Full Title: Effects of mannitol on delayed graft function after cadaveric renal transplantation

Medical condition: Kidney transplantation

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age:

Gender: Male, Female

Trial protocol: AT (Completed)

Trial results: (No results available)

EudraCT Number: 2005-005197-78

Sponsor Protocol Number: 1

Start Date:

Sponsor Name: Queen's Medical Centre, Nottingham, University Hospital NHS Trust,

Full Title: A multi-centre, randomised, parallel group, cross-over study comparing the efficacy and safety of double versus multiple injections of Botulinum Toxin type-A (Dysport®), into the gastrocnemius musc...

Medical condition: Spasticity of the Gastrocnemius Muscle due to Cerebral Palsy

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.0		10024132		LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2018-003281-14

Sponsor Protocol Number: FCR173011/ResToP

Start Date:

Sponsor Name: Fundación CRIS contra el Cáncer

Full Title: Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)

Medical condition: Chronic myelogenous leukemia

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10009012	Chronic myelogenous leukemia	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2009-011865-10

Sponsor Protocol Number: FINA-004

Start Date:

Sponsor Name: MerLion Pharmaceuticals GmbH

Full Title: An Open-label, Randomised, Multicentre, Multi-country Three-arm Study of the Treatment with Finafloxacin 400 mg b.i.d. plus Esomeprazole 40 mg b.i.d. for 14 days versus Finafloxacin 400 mg b.i.d. p...

Medical condition: Helicobacter pylori infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10019377	Helicobacter pylori infection	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) LT (Prematurely Ended) LV (Prematurely Ended) PL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2018-002880-25

Sponsor Protocol Number: LTE15174

Start Date:

Sponsor Name: Genzyme Corporation

Full Title: ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

Medical condition: Hemophilia A or Hemophilia B

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10060613	Hemophilia A (Factor VIII)	LLT
	20.0	100000004850	10060614	Hemophilia B (Factor IX)	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male

Trial protocol: IE (Restarted) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) HU (Ongoing) ES (Prematurely Ended) FR (Ongoing) DK (Temporarily Halted) Outside EU/EEA IT ()

Trial results: (No results available)

EudraCT Number: 2016-003361-25

Sponsor Protocol Number: SHP640-303

Start Date:

Sponsor Name: Shire Human Genetic Therapies, Inc.

Full Title: A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in...

Medical condition: Bacterial Conjunctivitis

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10021881 - Infections and infestations	10061784	Conjunctivitis bacterial	PT

Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) EE (Completed) HU (Completed) ES (Completed) PL (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2009-017709-12

Sponsor Protocol Number: Y-55-52120-141

Start Date:

Sponsor Name: Ipsen Pharma SAS

Full Title: A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WIT...

Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy.

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10024132	Leg spasticity	LLT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing) PL (Completed)

Trial results: (No results available)

EudraCT Number: 2020-005896-12

Sponsor Protocol Number: CBYL719F12401

Start Date:

Sponsor Name: Novartis Pharma AG

Full Title: EPIK-P3: A phase II study to evaluate the long-term safety and efficacy of alpelisib in patients with PIK3CA-Related Overgrowth Spectrum (PROS) who previously participated in Study CBYL719F12002 (E...

Medical condition: PIK3CA-related overgrowth spectrum (PROS)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10010331 - Congenital, familial and genetic disorders	10081236	PIK3CA related overgrowth spectrum	PT

Population Age: Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: FR (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2014-004201-33

Sponsor Protocol Number: Heparc-2007

Start Date:

Sponsor Name: Arrowhead Research Corporation

Full Title: A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with Chronic Hepatitis B Virus (HBV) Infection

Medical condition: Chronic Hepatitis B Virus Infection

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10021881 - Infections and infestations	10008910	Chronic hepatitis B	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

Últimos ensayos

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas